<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05072080</url>
  </required_header>
  <id_info>
    <org_study_id>EBSI-CV-317-004</org_study_id>
    <nct_id>NCT05072080</nct_id>
  </id_info>
  <brief_title>A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317</brief_title>
  <official_title>A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emergent BioSolutions</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emergent BioSolutions</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this multi-center, randomized, double blind, placebo controlled study is to&#xD;
      evaluate the safety and immunogenicity of PXVX0317 in healthy adult and adolescent subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coprimary Objectives:&#xD;
&#xD;
        1. To evaluate the safety of PXVX0317 in healthy adult and adolescent participants 12 to&#xD;
           &lt;65 years of age.&#xD;
&#xD;
        2. To compare the anti-CHIKV serum neutralizing antibody (SNA) response to PXVX0317 and&#xD;
           placebo at Day 22, as measured by geometric mean titer (GMT) and clinically relevant&#xD;
           difference in seroresponse rate.&#xD;
&#xD;
        3. To demonstrate the consistency of the anti-CHIKV SNA response across three lots of&#xD;
           PXVX0317 at Day 22.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        1. To compare the anti-CHIKV SNA response to PXVX0317 and placebo at Day 15, Day 183, and&#xD;
           Day 8.&#xD;
&#xD;
        2. To compare the anti-CHIKV SNA response to PXVX0317 and placebo in participants 12 to &lt;18&#xD;
           years of age, participants 18 to &lt;46 years of age, and participants 46 to &lt;65 years of&#xD;
           age.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 29, 2021</start_date>
  <completion_date type="Actual">April 3, 2023</completion_date>
  <primary_completion_date type="Actual">November 23, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomized in a 2:2:2:1 ratio within each age stratum (12 to &lt;18, 18 to &lt;46, and 46 to &lt;65). This study will be conducted in the US, using up to 50 sites.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of solicited Adverse Events (AE)</measure>
    <time_frame>8 days</time_frame>
    <description>Incidence of solicited AEs through Day 8 for PXVX0317 and placebo for all age strata combined (safety population).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of unsolicited AEs</measure>
    <time_frame>29 days</time_frame>
    <description>Incidence of unsolicited AEs through Day 29 for PXVX0317 and placebo for all age strata combined (safety population).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events of Special Interest (AESI)</measure>
    <time_frame>183 days</time_frame>
    <description>Incidence of AESIs, through Day 183 for PXVX0317 and placebo for all age strata combined (safety population).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Medically Attended Adverse Event (MAAE)</measure>
    <time_frame>183 days</time_frame>
    <description>Incidence of MAAEs through Day 183 for PXVX0317 and placebo for all age strata combined (safety population).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Serious Adverse Event (SAE)</measure>
    <time_frame>183 days</time_frame>
    <description>Incidence of SAEs through Day 183 for PXVX0317 and placebo for all age strata combined (safety population).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-CHIKV serum neutralizing antibody (SNA) seroresponse rates at Day 22</measure>
    <time_frame>22 days</time_frame>
    <description>Anti-CHIKV SNA seroresponse rates for PXVX0317 and placebo, difference (PXVX0317 minus placebo), and associated 95% confidence interval (CI) at Day 22 for the immunogenicity evaluable population (IEP), all age strata combined.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-CHIKV SNA geometric mean titers (GMT) at Day 22</measure>
    <time_frame>22 days</time_frame>
    <description>Anti-CHIKV SNA GMTs and associated 95% CIs at Day 22 for PXVX0317 and placebo for the IEP, all age strata combined.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-CHIKV SNA GMT ratios between pairs of PXVX0317 lots at Day 22</measure>
    <time_frame>22 days</time_frame>
    <description>Anti-CHIKV SNA GMT ratios and associated 95% CIs between all three pairs of PXVX0317 lots (A:B, A:C, B:C) in adults 18 to &lt;46 years of age in the IEP at Day 22.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-CHIKV SNA seroresponse rates at Days 15, 183, and 8</measure>
    <time_frame>183 days</time_frame>
    <description>Anti-CHIKV SNA seroresponse rates for PXVX0317 and placebo, difference (PXVX0317 minus placebo), and associated 95% CIs at Day 15, Day 183, and Day 8, in that order, for the IEP, all age strata combined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-CHIKV SNA Geometric Mean Titers (GMTs) at Days 8, 15, and 183</measure>
    <time_frame>183 days</time_frame>
    <description>Anti-CHIKV SNA GMTs with associated 95% CIs at Day 8, Day 15, and Day 183 for PXVX0317 and placebo for the IEP, all age strata combined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Increase (GMFI) in anti-CHIKV SNA titers from Day 1 to Days 8, 15, 22, and 183</measure>
    <time_frame>183 days</time_frame>
    <description>Geometric mean fold increase (GMFI) in anti-CHIKV SNA titers from Day 1 to Day 8, Day 15, Day 22, and Day 183 for the IEP for all age strata combined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of participants with anti-CHIKV SNA titer &gt;15 and 4-fold rise over baseline at Days 8, 15, 22, and 183</measure>
    <time_frame>183 days</time_frame>
    <description>Number and percentage of participants with anti-CHIKV SNA titers ≥15 and 4-fold rise over baseline at Day 8, Day 15, Day 22, and Day 183 for the IEP for all age strata combined.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">3258</enrollment>
  <condition>Chikungunya Virus</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1 - PXVX0317 lot A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 2 - PXVX0317 lot B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 3 - PXVX0317 lot C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group 4 - Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CHIKV VLP/adjuvant</intervention_name>
    <description>PXVX0317 vaccine is comprised of chikungunya virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide (Alhydrogel®) adjuvant 2%</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo is comprised of formulation buffer</description>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able and willing to provide informed consent (and assent, as applicable) voluntarily&#xD;
             signed by participant (and guardian, as applicable).&#xD;
&#xD;
          -  Males or females, 12 to &lt;65 years of age.&#xD;
&#xD;
          -  Generally healthy, in the opinion of the investigator, based on medical history,&#xD;
             physical examination, and screening laboratory assessments.&#xD;
&#xD;
          -  Women who are either: (i) Not of childbearing potential (CBP): pre-menarche,&#xD;
             surgically sterile (at least six weeks post bilateral tubal ligation, bilateral&#xD;
             oophorectomy or hysterectomy), or postmenopausal (defined as a history of ≥12&#xD;
             consecutive months without menses prior to randomization in the absence of other&#xD;
             pathologic or physiologic causes, following cessation of exogenous sex-hormonal&#xD;
             treatment) or (ii) Meeting all the below criteria: Negative serum pregnancy test at&#xD;
             screening visit, Negative urine pregnancy test immediately prior to dosing at Day 1,&#xD;
             Using an acceptable method of contraception (if women of CBP) for the duration of&#xD;
             participation, such as hormonal contraceptives (eg, implants, pills, patches)&#xD;
             initiated ≥30 days prior to dosing, intrauterine device (IUD) inserted ≥30 days prior&#xD;
             to dosing, double barrier type of birth control (male condom with female diaphragm,&#xD;
             male condom with cervical cap), Abstinence is acceptable only for adolescents (12 to&#xD;
             &lt;18 years old) who are not sexually active.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently pregnant, breastfeeding, or planning to become pregnant during the study.&#xD;
&#xD;
          -  Body Mass Index (BMI) ≥35 kg/m2.&#xD;
&#xD;
          -  Positive laboratory evidence of current infection with human immunodeficiency virus&#xD;
             (HIV-1, HIV-2), hepatitis C virus (HCV) or hepatitis B virus (HBV).&#xD;
&#xD;
          -  History of severe allergic reaction or anaphylaxis to any component of the vaccine.&#xD;
&#xD;
          -  History of any known congenital or acquired immunodeficiency that could impact&#xD;
             response to vaccination (eg, leukemia, lymphoma, generalized malignancy, functional or&#xD;
             anatomic asplenia, alcoholic cirrhosis).&#xD;
&#xD;
          -  Prior receipt or anticipated use of systemic immunomodulatory or immunosuppressive&#xD;
             medications from six months prior to screening through Day 22. Note: For systemic&#xD;
             corticosteroids, use at a dose or equivalent dose of 20 mg of prednisone daily for 14&#xD;
             days or more within three months of screening through Day 22 is exclusionary. The use&#xD;
             of inhaled, intranasal, topical, ocular, or intraocular steroids is allowed.&#xD;
&#xD;
          -  Receipt or anticipated receipt of blood or blood-derived products from 90 days prior&#xD;
             to screening through Day 22.&#xD;
&#xD;
          -  Acute disease within the last 14 days (participants with an acute mild febrile illness&#xD;
             can be considered for a deferral of vaccination two weeks after the illness has&#xD;
             resolved and treatment has been completed).&#xD;
&#xD;
          -  Clinically significant cardiac, pulmonary, rheumatologic, or other chronic disease, in&#xD;
             the opinion of the investigator. This may include chronic illness requiring&#xD;
             hospitalization in the last 30 days prior to screening.&#xD;
&#xD;
          -  Enrollment in an interventional study and/or receipt of another investigational&#xD;
             product from 30 days prior to screening through the duration of study participation.&#xD;
&#xD;
          -  Receipt or anticipated receipt of any vaccine from 30 days prior to Day 1 through Day&#xD;
             22.&#xD;
&#xD;
          -  Evidence of substance abuse that, in the opinion of the investigator, could adversely&#xD;
             impact the participant's participation or the conduct of the study.&#xD;
&#xD;
          -  Prior receipt of an investigational CHIKV vaccine/product.&#xD;
&#xD;
          -  Any other medical condition that, in the opinion of the investigator, could adversely&#xD;
             impact the participant's participation or the conduct of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Ajiboye, MD</last_name>
    <role>Study Director</role>
    <affiliation>Emergent BioSolutions</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Optimal Research, LLC</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research - Mobile</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research, LLC</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research, Banning</name>
      <address>
        <city>Banning</city>
        <state>California</state>
        <zip>92220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimal Research, LLC</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Institute of the Rockies</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80918</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacksonville Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accel Research Sites-DeLand Clinical Research Unit</name>
      <address>
        <city>Lake Mary</city>
        <state>Florida</state>
        <zip>32746</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimal Research, LLC</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32934</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suncoast Research Associates, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc.</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Beach Research Center</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research, Boise</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc.</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimal Research LLC</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johnson County ClinTrials</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research, LLC</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research - Wichita East</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research, LLC</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research, LLC</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimal Research, LLC</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research - Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc.</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wr-Crcn, Llc</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research, LLC.</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Clinical Research, Inc.</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M3 Wake Research, Inc</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trial Management Associates, LLC</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center - The Gamble Vaccine Research Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Rsearch, Inc.</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aventiv Research Inc.</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Institute of Norman</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Health Science Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research, Medford</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research-Providence</name>
      <address>
        <city>East Greenwich</city>
        <state>Rhode Island</state>
        <zip>02818</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc.</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center</name>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <zip>29405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research, LLC</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research, Austin</name>
      <address>
        <city>Cedar Park</city>
        <state>Texas</state>
        <zip>78613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Center for Drug Development, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Your Health</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BFHC Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DM Clinical Research</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research, LLC</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>September 28, 2021</study_first_submitted>
  <study_first_submitted_qc>September 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2021</study_first_posted>
  <last_update_submitted>April 12, 2023</last_update_submitted>
  <last_update_submitted_qc>April 12, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chikungunya</keyword>
  <keyword>VLP</keyword>
  <keyword>PXVX0317</keyword>
  <keyword>vaccine</keyword>
  <keyword>immunogenicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chikungunya Fever</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

